MedPath

Adavosertib

Generic Name
Adavosertib
Drug Type
Small Molecule
Chemical Formula
C27H32N8O2
CAS Number
955365-80-7
Unique Ingredient Identifier
K2T6HJX3I3
Background

MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Clinical Trials
Related News

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Phase 1
Completed
Conditions
Refractory Solid Tumours
Relapsed Small Cell Lung Cancer (SCLC)
Interventions
First Posted Date
2015-07-30
Last Posted Date
2019-11-07
Lead Sponsor
AstraZeneca
Target Recruit Count
128
Registration Number
NCT02511795
Locations
🇨🇦

Research Site, Toronto, Ontario, Canada

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Phase 1
Completed
Conditions
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions
First Posted Date
2015-06-26
Last Posted Date
2023-07-03
Lead Sponsor
AstraZeneca
Target Recruit Count
92
Registration Number
NCT02482311
Locations
🇨🇦

Research Site, Toronto, Ontario, Canada

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2
Active, not recruiting
Conditions
Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Bladder Carcinoma
Breast Carcinoma
Cervical Carcinoma
Colon Carcinoma
Colorectal Carcinoma
Endometrial Carcinoma
Esophageal Carcinoma
Exocrine Pancreas Carcinoma
Interventions
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Cytology Specimen Collection Procedure
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography Test
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Procedure: Radionuclide Imaging
First Posted Date
2015-06-08
Last Posted Date
2025-05-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
6452
Registration Number
NCT02465060
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Thomas Hospital, Fairhope, Alabama, United States

🇺🇸

Mobile Infirmary Medical Center, Mobile, Alabama, United States

and more 1406 locations

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Phase 2
Completed
Conditions
Advanced Gastric Adenocarcinoma
Interventions
First Posted Date
2015-05-19
Last Posted Date
2022-06-15
Lead Sponsor
Samsung Medical Center
Target Recruit Count
26
Registration Number
NCT02448329
Locations
🇰🇷

Samsung Medical center, Seoul, Korea, Republic of

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
Myelodysplastic Syndrome
Untreated Adult Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2015-03-06
Last Posted Date
2018-05-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT02381548
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Phase 1
Completed
Conditions
Advanced Solid Tumours
Interventions
First Posted Date
2015-01-19
Last Posted Date
2019-03-25
Lead Sponsor
AstraZeneca
Target Recruit Count
19
Registration Number
NCT02341456
Locations
🇰🇷

Research Site, Seoul, Korea, Republic of

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2
Completed
Conditions
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions
Drug: PLD
First Posted Date
2014-10-23
Last Posted Date
2023-10-03
Lead Sponsor
AstraZeneca
Target Recruit Count
95
Registration Number
NCT02272790
Locations
🇳🇱

Research Site, Amsterdam, Netherlands

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1
Completed
Conditions
Metastatic Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7
Unresectable Pancreatic Carcinoma
Interventions
First Posted Date
2014-07-18
Last Posted Date
2023-04-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
8
Registration Number
NCT02194829
Locations
🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 2 locations

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2
Active, not recruiting
Conditions
Ovarian Carcinosarcoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Surface Papillary Adenocarcinoma
Ovarian Undifferentiated Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Ovarian Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Recurrent Ovarian Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Placebo Administration
Other: Questionnaire Administration
First Posted Date
2014-04-02
Last Posted Date
2025-04-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
124
Registration Number
NCT02101775
Locations
🇨🇦

University Health Network Princess Margaret Cancer Center P2C, Toronto, Ontario, Canada

🇺🇸

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇨🇦

BCCA-Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 13 locations

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 1
Completed
Conditions
Primary Central Nervous System Neoplasm
Recurrent Rhabdomyosarcoma
Refractory Malignant Solid Neoplasm
Central Nervous System Ganglioneuroblastoma
Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
Recurrent Childhood Central Nervous System Embryonal Neoplasm
Pineoblastoma
Refractory Medulloblastoma
Refractory Neuroblastoma
Central Nervous System Embryonal Tumor With Rhabdoid Features
Interventions
First Posted Date
2014-03-24
Last Posted Date
2023-09-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
76
Registration Number
NCT02095132
Locations
🇺🇸

C S Mott Children's Hospital, Ann Arbor, Michigan, United States

🇺🇸

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States

🇺🇸

Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

and more 21 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy